Trial Profile
Phase II Study Of Lenalidomide and Rituximab in Patients With treatment naive and relapsed Chronic Lymphocytic Leukemia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Jan 2019
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 04 Dec 2018 Results assessing efficacy of lenalidomide and rituximab combination in chronic lymphocytic patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2016 Results (n= 129) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 13 Aug 2014 New trial record